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Objective: To determine the value of bone markers in early-stage progressive knee osteoarthritis (OA), a
population-based cohort of middle-aged subjects with chronic knee complaints was followed over 6
years (two consecutive two 3-year periods).
Methods: Tibiofemoral (TF) and patellofemoral (PF) radiographs were graded in 128 subjects (mean age
at baseline 45  6.2 years) in 2002, 2005 and 2008. Bone formation was assessed by the serum con-
centration of procollagen type I amino-terminal propeptide (sPINP); bone resorption by the level of the
C-terminal cross-linked telopeptides of type I collagen (sCTx-I); and bone mineralization by the values of
osteocalcin (sOC) by electrochemiluminescence immunoassay. A novel marker of bone resorption, uri-
nary osteocalcin midfragments (uMidOC), was assayed using enzyme linked immunosorbent assay
(ELISA).
Results: Several diagnostic associations were found between the bone markers (PINP, OC, MidOC) and
progressive OA expressed by TF osteophytosis. The increasing output of MidOC demonstrated several-
fold higher risk for progressive TF osteophytosis [odds ratio (OR) 5.32; 95% conﬁdence interval (CI)
1.41e20.06, P ¼ 0.014] than other bone markers. The values of PINP had prognostic value for subsequent
more severely expressed knee OA progression [r(s) ¼ 0.460, P ¼ 0.005].
Conclusions: Bone metabolism is activated in early-stage knee OA. OA progression was preceded by the
enhanced bone formation (by PINP) and accompanied by the activation of bone formation (by PINP),
non-collagenous bone resorption (by MidOC), as well as by changes in mineralization (by OC). All three
bone markers had diagnostic value, and one of them, PINP, had also a predictive value for knee OA
progression, especially for progressive osteophytosis.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a disease of the whole joint, which affects,
besides articular cartilage, also juxtaarticular bone, including
osteophyte formation and subchondral changes, leading ﬁnally to
sclerosis1e4. Already two decades ago it was suggested that bone
rather than cartilage may be responsible for the initial patho-
physiological events in OA5e7. Moreover, bisphosphonates, potent
inhibitors of bone resorption, have been shown to reduce cartilage
degeneration, osteophyte formation and bone resorption in both
experimental and human OA8,9. Nevertheless, bone involvement
has received only scant attention in OA.J. Kumm, University of Tartu,
014, Estonia. Tel: 372-7-319-
mm).
s Research Society International. PIn knee OA (KOA), the metabolic activity of bone has been
characterized by two types of biomarkers: reﬂecting resorption of
type I collagen (C-and N-telopeptides) and/or bone mineralization
(serum bone sialoprotein e BSP or osteocalcin e OC). There is
limited information about to what extent bone markers are able to
reﬂect the presence of OA and its progression. Unfortunately,
available studies have yielded conﬂicting data10. It is even unclear
whether OA is characterized by increased11e14 or decreased10,15
bone turnover.
It has been shown that urinary OC is a heterogeneous pool of
various OC fragments consisting mainly of the middle portion of
the molecule, of the sequence Gly7eGlu3116. Studies in post-
menopausal women with osteoporosis receiving bisphosphonate
therapy have provided evidence of these urinary midfragments of
OC (MidOC) behaving similarly to a well-known marker of bone
resorption, CTx-I17e19. While urinary OC reﬂects the diverse
degradation cascades in non-collagenous bone, CTx-I, is cleavedublished by Elsevier Ltd. All rights reserved.
Table II
The prevalence of radiographic KOA at baseline and 6-year follow-up
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combined action of matrix metalloproteinases (MMPs) and
cathepsin K secreted by osteoclasts20. It has even been suggested
that the urinary OC fragments may be more speciﬁc for bone
resorption than the type I collagen relatedmarkers20. So far, urinary
OC midfragments have not been tested in OA patients.
The role of synthesis of type I collagen (reﬂected by levels of
procollagen type I N-propeptide, PINP) has been largely overlooked.
Recently, in a 2-year follow-up study in patients with a mean age of
64 years, Berry et al. demonstrated that among other bone markers,
serum values of PINP had a prognostic value for magnetic reso-
nance imaging (MRI)-detected cartilage loss21. The majority of OA
studies have focused predominantly on advanced disease. Thus,
there is a signiﬁcant lack of knowledge regarding the utility of bone
markers in early-stage KOA. Moreover, only single bone markers
have been studied in early KOA.
To determine the value of bone markers in early-stage pro-
gressive KOA, we used a set of markers, among them a newmarker,
uMidOC16. This set of biomarkers was implemented in a
population-based cohort of middle-aged subjects with chronic
knee complaints over 6 years (two prospective 3-year periods).
Methods
Study group
Subjects with persistent knee complaints were identiﬁed using
a questionnaire sent to a random sample of individuals aged 35e55
from the register of a general practitioner22. An initial invitation to
participate in the study was sent to 559 randomly selected subjects.
Of those, 348 (62%) responded. Out of the responders, 220 admitted
either knee pain (60%) or other symptoms (40%) such as crepitation
and stiffness. Out of those, 161 (73%) agreed to participate in the
longitudinal study and were examined at three different time
points, at baseline (in 2002), after 3 (in 2005) and 6 (in 2008) years.
Over the 6 years, 33 subjects (20%) were lost to follow-up. The
reasons for participants being not eligible for follow-up included
refusal (n ¼ 21), leaving the study area (n ¼ 9), death (n ¼ 1), and
inability to contact (n ¼ 2).
Knee joint radiographs were available for at least two time
points, the baseline and at the end of the study, for 128 subjects
whowere included in the present study. The patient characteristics
are presented in Table I.
The distribution of age, gender and body mass index (BMI) of
these 128 subjects did not differ signiﬁcantly from the initial groupTable I
Characteristics of the study participants
Characteristics Study group at baseline (n ¼ 161)
Returned
(n ¼ 128)
Lost to follow-up
(n ¼ 33)
P*
Baseline age, mean  SD years 45.0  6.2 46.9  5.4 0.116
Baseline BMI, mean  SD kg/m3 27.6  5.1 27.7  5.4 0.928
Women 85/128 (66%) 16/33 (48%) 0.417
Baseline radiographic KOAy 73/128 (57%) 21/33 (64%) 0.752
Baseline radiographic KOA
grade 2e3z
7/128 (5.5%) 1/33 (3%) 0.100
There were no statistically signiﬁcant differences in mean age or BMI between the
female and the male subjects. The proportion of post-menopausal women was 35%
at baseline and 45% at the end of the study.
Except where indicated otherwise values denote the number/total number (%) of
patients.
* By the chi-square test for categorical variables and by the ManneWhitney U test
for continuous variables.
y KOA grades 1, 2 and 3 according to the grading system of Nagaosa.
z KOA grades 2 and 3 according to the grading system of Nagaosa.of 220 individuals. Subjects with radiographic evidence of inﬂam-
matory arthropathies in the knees were not included in the study.
Written consent for participation was obtained according to the
Declaration of Helsinki. The study protocol was approved by the
Ethics Committee for Human Research of the University of Tartu.
Radiographic investigation and description of radiographic
progression
Standardized radiographs of the tibiofemoral (TF) joints of both
knees were taken with the subject in a standing antero-posterior
position with the joint in full extension and with equal weight on
both legs. Axial views of the patellofemoral (PF) joints were taken
in a standing position, with knee at 60 ﬂexion according to the
technique described by Boegard et al.23
Joint space narrowing (JSN) and osteophyte sizes were classiﬁed
on four-point scales according to the system of Nagaosa et al.24 This
system enables the grading of JSN and osteophytes separately in the
TF and PF compartments and has advantages over the Kellgrene
Lawrence system in the case of an earlier disease24. Osteophyte size
was determined in eight distinct regions of interest (ROIs): medial
and lateral femoral, tibial, patellar and femoral trochleal. TFOA and
PFOA grades were deﬁned for both knees as the highest grades
documented in any ROI. Radiographic OA (ROA) grade 1 was diag-
nosed if at least one deﬁnite osteophyte (grade 1) and/or JSN (grade
1) was assessed in any ROI. The OA grade 2 was diagnosed if grade 2
osteophyte and/or JSN was assessed in any ROI. The OA grade 3 was
assigned if grade 3 osteophyte and/or JSN was assessed in any ROI.
The criteria for ROA progression were deﬁned as: (1) presence of
osteophytes and/or JSN in subjects with no previous radiographic
evidence of OA, or (2) increase in the grade and/or number of
existing osteophytes and/or JSN grade over follow-up.
All radiographs were interpreted by an experienced radiologist
(ML) who was blind to clinical details. Radiographs from different
time points were examined in pairs to ensure consistent evaluation
over time25.
The ROA ﬁndings of the present cohort were previously
described in detail26. Brieﬂy, over 6 years, we observed ROA grade
progression in 71 subjects (56%; Table II). Mostly we observed TFOA
progression from grade 0 to grade 1. At the same time, 20 subjects
showed no evidence of OA grade progression but had developedOA grade At baseline (2002) At 6-yr follow-up (2008)
OA grade 0 56 (44%) 23 (18%)
OA grade 1 65 (51%) 86 (67%)
TFOA ¼ 1 20 24
PFOA ¼ 1 25 16
TFOA þ PFOA ¼ 1 20 46
OA grade 2 6 (4%) 16 (13%)
TFOA ¼ 2 3 7
PFOA ¼ 2 1 6
TFOA þ PFOA ¼ 2 2 3
OA grade 3 1 (<1%) 3 (2%)
TOTAL 128 128
The numbers and percentages of different radiographic KOA grades at baseline and
at 6-year follow-up.
At baseline, out of the 72 subjects with radiographic KOA, the diagnosis was based
on osteophytes alone in 57%, on isolated JSN in 13%, and on both in 30%.
Note that, at 6-year follow-up, out of the subjects with OA grade 1, approximately
60% had both TFOA and PFOA in combination, twice as high percentage as at
baseline. Compared to baseline, 12 new subjects were diagnosed with OA grades 2e
3. Altogether, over 6 years, ROA grade progression was observed in 71 subjects out
of 128 (56%). When the features of OA were analyzed separately, 31 (43.7%) subjects
showed progression only in osteophytes alone, 14 (19.7%) in JSN alone, and 26
(36.6%) in osteophytes and JSN in combination.
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revealed no radiographic changes. The number of TFOA progressors
was signiﬁcantly higher over the ﬁrst 3 years of follow-up when
compared to the last 3 years. In the majority of cases, TFOA pro-
gression did not proceed during the second period of observation26.
Thus, the course of ROA followed a non-continuous pattern with
periods of progression and intermittent stops26.
Laboratory investigations
Fasting morning serum samples were obtained at three time
points, and second-morning urinary void samples were collected at
the 3- and 6-year follow-ups all in summer season. All samples
were stored frozen at 70C until measured.
Bone formation was assessed by the serum concentration
of procollagen type I amino-terminal propeptide (sPINP), and
bone resorption, by the serum level of the C-terminal cross-linked
telopeptides of type I collagen (sCTx-I) (electrochemiluminescence
immunoassay, Roche, Elecsys). The non-collagenous marker
osteocalcin (sOC) was used to reﬂect overall bone turnover and
mineralization. For this, the serum concentration of OC was
assayed using the same method by Roche.
A novel marker of bone resorption, uMidOC16,27, was assayed as
described by Ivaska et al.16 The values of MidOC were normalized
for urinary creatinine, which was measured by Jaffe’s kinetic
method.
Intra-assay variation for PINP, CTx-I, OC andMidOCwas 3%,<4%,
<4% and <2.7%, respectively, and inter-assay variation was 3%, 12%,
5% and 8%, respectively.
Statistics
Descriptive statistics were calculated for sex, age, and presence
of ROA grades and compared between subjects who had returned
and those who were lost to follow-up by chi-square test for cate-
gorical variables and by the ManneWhitney U test for continuous
variables.
As biomarker values did not follow normal distribution, non-
parametric methods were used for statistical evaluation. The
diagnostic and prognostic value of each biomarker for ROA pro-
gressionwas assessed by the ManneWhitney U test, comparing the
values of the bone markers for the OA progressors and the non-
progressors. The associations between the bone marker values
and progression of ROA features were assessed by Spearman’s rank
correlations. The risk of ROA progression with increasing bone
marker values was calculated by logistic regression analysis [odds
ratios (ORs)] and alternatively with Poisson regression analysis
with robust error variance, with adjustment for age, gender and
BMI. Receiver operating characteristic (ROC) curves were used to
estimate the area under the curve (AUC) for bone marker values
predicting KOA progression. A P value <0.05 was considered sta-
tistically signiﬁcant.
Results
Bone markers over a 6-year follow-up if KOA progression was
expressed by global OA grades
In general, there was no statistically signiﬁcant difference in the
values of bone markers between the progressors and non-
progressors when we focused only on changes in global OA
grades (TFOA, PFOA). However, a single exceptionwas noted for the
levels of sPINP, whose baseline concentrations were signiﬁcantly
higher in subjects who developed subsequent simultaneous
TFOA and PFOA grade progression over 6 years; the medianconcentrations for the progressors and the non-progressors were
59.3 (n ¼ 9) and 44.6 (n ¼ 21) ng/mL, respectively; P ¼ 0.009. A
signiﬁcant positive correlation between TFOA þ PFOA grade pro-
gression and baseline values of PINP was also observed
[r(s) ¼ 0.481, n ¼ 30, P ¼ 0.008].
Several associations were found when the radiographic pro-
gression of OA was assessed separately for JSN and osteophytes.
The diagnostic and prognostic value of the bone markers if ROA
progression was expressed separately by osteophytes and JSN
No statistically signiﬁcant association was observed between
values of bone markers and progressive JSN for any knee joint
location. However, a signiﬁcant positive correlation was observed
between baseline values of sPINP and subsequent progressive TF
and PF osteophytosis over the 3-year follow-up [r(s) ¼ 0.33, n ¼ 44,
P ¼ 0.029]. The medians of PINP for the progressors and non-
progressors were 45.2 (n ¼ 29) and 39.4 (n ¼ 15) ng/mL, respec-
tively; P ¼ 0.030. This correlation indicates the prognostic value of
the bone marker PINP for progressive osteophytosis. At the same
time, no diagnostic association was observed between values of
PINP and progressive osteophytosis. In addition, no statistically
signiﬁcant diagnostic or prognostic association between values of
the other studied bone markers, CTx-I, OC and MidOC, and pro-
gressive osteophytosis was found.
The diagnostic and prognostic value of the bone markers in case
distinct forms of progressive OA were differentiated
In the following analysis, we differentiated between speciﬁc
radiographic subgroups of progressive OAwith isolated progression
of only JSN (without progressive osteophytosis), of only osteo-
phytes (without progressive JSN), with progression in only the TF
compartment, or with simultaneous progression of osteophytes
and JSN in several knee joint compartments (so called “extensive
progression”). This approach revealed more diagnostic as well as
prognostic associations between bone markers and progressive
KOA. As the radiographic course of KOA over 6 years was non-
continuous (see Methods), the values of the bone markers were
assessed separately for the two consecutive 3-year periods e
2002e2005 and 2005e2008.
First 3 years of follow-up (2002e2005)
Prognostic value: The baseline values of sPINP were signiﬁ-
cantly higher in the subgroup of patients with more extensive
progression of OA compared to the non-progressors [r(s) ¼ 0.460,
n ¼ 35, P ¼ 0.005; Tables III and V].
Diagnostic value: The values of sPINP and sOC (assayed at the
3-year follow-up) had a signiﬁcant positive correlation with iso-
lated progressive TF osteophytosis during the ﬁrst 3 years of follow-
up [r(s) ¼ 0.350, n ¼ 33, P ¼ 0.046 and r(s) ¼ 0.458, n ¼ 33,
P ¼ 0.007, respectively]. The median concentrations of PINP and OC
for the osteophyte progressors versus non-progressors are pre-
sented in Table III. A similar associationwas observed for the values
of sOC (assayed at the 3-year follow-up) in subjects in whom dis-
ease progression was conﬁned to the TF compartment [TF osteo-
phytes and/or TF JSN; r(s) ¼ 0.355, n ¼ 42, P ¼ 0.007; Table III].
At the same time, no statistically signiﬁcant correlation was
observed between the values of sCTx-I or uMidOC and the above-
described distinct forms of progressive KOA.
Subsequent 3 years of follow-up (2005e2008)
Over the following 3 years only a single association was found
between bone markers and progressive KOA: baseline values of
sPINP were positively correlated with subsequent extensive
Table III
Median concentrations of the bone markers for speciﬁc subgroups of ROA progression over the ﬁrst 3 years of follow-up
Bone marker Type of OA progression Gender Progression No OA P Observed role
PINP at baseline Extensive progression* M þ F 58.2 (n ¼ 11) 42.3 (n ¼ 24) 0.006 Predictive
F 64.0 (n ¼ 11) 38.1 (n ¼ 12) 0.0002
PINP at 3-year follow-up Isolated TF osteophytesy M þ F 50.2 (n ¼ 16) 36.4 (n ¼ 18) 0.036 Diagnostic
OC at 3-year follow-up Isolated TF osteophytesy M þ F 26.1 (n ¼ 16) 18.6 (n ¼ 18) 0.005 Diagnostic
F 34.2 (n ¼ 11) 18.6 (n ¼ 12) 0.013
OC at 3-year follow-up Isolated TF involvementz M þ F 24.5 (n ¼ 38) 18.6 (n ¼ 13) 0.008 Diagnostic
F 24.3 (n ¼ 29) 18.1 (n ¼ 13) 0.012
The numbers in the parentheses represent the number of patients with a distinct type of radiographic progression and the number of subjects without radiographic KOA.
Differences in the medians between the progressive OA and no OA groups were calculated by the ManneWhitney U test.
* Simultaneous progressive osteophytosis with or without progressive JSN in multiple knee joint compartments.
y OA progression expressed only by TF osteophytes (without simultaneous progressive TF JSN or PF involvement).
z OA progression only in the TF compartment (TF osteophytes and/or TF JSN), without simultaneous PF involvement.
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values of sPINP for the progressors compared to the non-
progressors were 58.2 (n ¼ 7) and 39.8 (n ¼ 18) ng/mL, respec-
tively; P ¼ 0.013. The latter association again indicates the prog-
nostic value of PINP for ROA progression when the subgrouping of
the patients was applied. At the same time, no diagnostic value of
PINP for KOA progression was observed over the last 3 years of
follow-up (Table V). Moreover, no diagnostic or prognostic value of
CTx-I, OC and MidOC, was found.Risk of KOA progression with increasing values of the bone markers
In the present study, logistic regression analysis was performed
to quantitatively assess (by ORs) the potential risk associations
between KOA progression and bone markers. The risk of TF osteo-
phyte progression was signiﬁcantly increased with the increasing
levels of sOC and uMidOC, in comparisonwith the non-progressors
(Table IV). Increasing values of MidOC were associated with even
several-fold higher risk for isolated TF osteophyte progression
when compared to the values of OC.
The above results are summarized in Table V to demonstrate the
diagnostic and prognostic value of studied bone markers for pro-
gressive KOA. The behavior of biomarkers was clearly different over
6 years. Three bonemarkerse PINP, OC andMidOCe expressed the
diagnostic value for progressive KOA over the ﬁrst 3 years of follow-
up. Over the last 3 years of follow-up, however, no diagnostic as-
sociation was observed between bone markers and progressive
KOA. Only one of the studied biomarkers, the bone formation
marker PINP, had a prognostic value for OA progression over both
assessed time periods.
There was, however, no diagnostic or prognostic association
between CTx-I and progressive OA at any time point.Table IV
Statistically signiﬁcant associations between bone markers and radiographic sub-
groups of KOA progression: risk of OA progression
Bone
marker*
Type of OA progression over
ﬁrst 3 years of follow-up
OR (95% CI) P value n
OC Isolated TF osteophytesy 1.34 (1.05e1.72) 0.021 16
OC TF osteophytes þ TF JSNz 1.09 (1.00e1.18) 0.047 13
MidOC TF osteophytes 2.68 (1.00e7.19) 0.050 34
MidOC Isolated TF osteophytesy 5.32 (1.41e20.06) 0.014 16
MidOC TF þ PF osteophytes 2.50 (1.03e6.07) 0.043 44
All analyses were adjusted for age, gender, and BMI.
By logistic regression analysis
* All presented bone markers were assayed at 3-year follow-up (in 2005).
y OA progression expressed only by TF osteophytes without simultaneous pro-
gressive TF JSN or PF involvement.
z OA progression only in the TF compartment (TF osteophytes and/or TF JSN),
without simultaneous PF involvement.Discussion
There is still minimal data on the value of bone markers in pa-
tients with early-stage OA. A single work by Petersson et al.11,
conducted in middle-aged KOA patients, demonstrated that levels
of sBSP, a marker of bone matrix mineralization, were signiﬁcantly
increased in patients with ROA11. However, no predictive associa-
tion between BSP and OA was found. The bone marker studies
performed in elderly patients with advanced KOA have demon-
strated quite conﬂicting data. A longitudinal study by Bettica et al.
reported higher values of bone resorptionmarkers (uCTx-I, uNTx-I)
in progressive KOA14, while in another study, conducted by Bruyere
et al., no association between CTx-I and 12-month loss in MRI-
detected cartilage thickness was found28. Previous studies have
mainly focused on bone resorption markers reﬂecting degradation
of type I collagen. At the same time, the other aspect of bone
turnover e synthesis of bone collagen (by PINP) e has not been
routinely assessed. Instead of PINP, serum levels of OC have been
assayed as a measure of bone formation10,28,29. However, serum
total OC is a complex marker of non-collagenous origin that em-
braces molecular fragments also reﬂecting bone resorption16,17. Its
biologic function is considered to be related to the inhibition of
bone matrix mineralization30. Thus, sOC should not be regarded as
a marker of merely bone formation. Our previous study in patients
with osteoporosis receiving risedronate therapy established that
the values of urinary OCmidfragments (MidOC) changed in parallel
to the values of well-known bone resorption marker CTx-I19.
In the present study, we investigated simultaneously the syn-
thetic, resorptive andmineralization aspects of bone metabolism in
early-stage progressive and non-progressive KOA. We assayed en
bloc speciﬁc markers of type I collagen synthesis (PINP) and
resorption (CTx-I), as well as a non-collagenous marker, osteocalcin
(OC), and a novel non-collagenous marker of bone resorptionTable V
The diagnostic and prognostic value of the bone markers for radiographic KOA
progression over two 3-year follow-up periods
Bone
marker
First 3 years of follow-up
(2002e2005)
Last 3 years of follow-up
(2005e2008)
Diagnostic
value
Prognostic
value
Diagnostic
value
Prognostic
value
sPINP Yesy Yes* No Yes*
sOC Yesy No No No
sCTx-I No No No No
uMidOC Yesy No No No
The observed diagnostic and prognostic values are schematically presented for all
studied bone markers for KOA progression over the two follow-up periods.
* Bone marker assayed at baseline (in 2002).
y Bone marker assayed at 3-year follow-up (in 2005).
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to evaluate the behavior of uMidOC in KOA patients.
Unlike many earlier studies, we classiﬁed ROA according to the
grading system of Nagaosa et al.24 The widely used Kellgrene
Lawrence system represents a global assessment of OA and has only
advantages for amore severe disease24,31. Also, it has been criticized
for its relative insensitivity to dynamic changes and poor repro-
ducibility32. At present, it has become clear that increased detail is
muchmore appropriate in the interpretation of joint radiographs33.
Therefore, in the present study, ROA progression was assessed in
two different ways: by global OA grades and separately by OA
features e osteophytes and JSN. Recently, the latter approach has
been strongly recommended for biomarker studies, as JSN and
osteophytes involve different pathophysiologies33. Unlike previous
studies focusing on OA grades 2e3, we focused on grade 1 as well,
which led to the most prevalent ﬁnding in our cohort of middle-
aged subjects with chronic knee complaints. As we followed up
patients whose mean age was only 45 years and who had mostly
KOA grade 1, we treated the cohort as subjects suffering from early
ROA. In our previous study we followed up the same cohort
radiographically over 6 years and observed a non-consistent course
of the disease with periods of radiographic progression and stabi-
lization26. Therefore, the duration of the present bonemarker study
was divided into two consecutive 3-year periods.
Our results on the associations between bonemarker values and
progressive ROA supported the view that global OA grades fail to
reveal information about the early disease33. Indeed, whenwe used
global ROA grades, only a single positive correlation was observed
between 6-year progression in TFOA þ PFOA grade and serum
values of PINP. However, when JSN and osteophytes were analyzed
separately and some radiographic forms of progressive KOA were
differentiated, we were able to demonstrate several diagnostic and
prognostic values of the bone markers for progressive KOA.
According to BIPED criteria (which stands for Burden of disease,
Investigative, Prognostic, Efﬁcacy of intervention and Diagnostic),
biomarkers are presumed to have a diagnostic and prognostic cate-
gory of performance34. We established that progressive TF osteo-
phytosis was accompanied by the activation of bone formation (by
PINP), bone resorption (by MidOC), and by changes in bone mineral-
ization (by OC), providing evidence of the diagnostic value of these
biomarkers. It is important to note that the association between
progressive osteophytosis and bone resorption was reﬂected only by
the novel non-collagenousmarker MidOC but not by thewell-known
collagen type I degradation marker CTx-I. This discrepancy indicates
that these two bone resorption markers represent qualitatively
different aspects of bone degradation. Based on these results, we can
speculate that the course of KOA comprised a certain sequence of
events. Changes in bone formation and mineralization, as well as in
the degradation of non-collagenous part of bone, precede the collag-
enous side of bone degradation. However, this hypothesis needs
further clariﬁcation through larger experimental and clinicalmaterial.
Interestingly, over subsequent 3 years, no diagnostic association
was observed between the above bone markers and progressive
OA, indicating a metabolically non-continuous course of KOA. This
ﬁnding is in accordance with our 6-year radiographic data from the
same cohort that revealed a non-continuous course of KOA with
periods of progression and stabilization. Moreover, radiographi-
cally, markedly fewer cases of OA progression were found over the
last 3 years of follow-up when compared to the ﬁrst 3 years
(described in Methods)26. Thus, we established a metabolically and
radiographically non-continuous course of KOA. In the second
period of follow-up, we observed fewer cases of radiographic pro-
gression as well as lower metabolic activity of bone tissue.
It is important to elucidate what kind of biomarkers could
signal subsequent likely progression of OA. In our material,progressive osteophytosis as well as more extensive KOA pro-
gression (i.e., combined OA progression in several knee com-
partments), was preceded by the activation of the synthesis of
type I collagen (by PINP; Table III; Appendix Fig. 4). This ﬁnding
provides evidence of the prognostic value of PINP for progressive
KOA. At the same time, no prognostic value was found for the
other bone markers. The enhanced synthesis of bone collagen
possibly reﬂects the activation of reparative processes in KOA. At
the same time, there was no prognostic association between the
bone resorption markers and progressive OA. Later, when the
disease had already progressed, enhanced non-collagenous bone
resorption was evident.
The ﬁndings of the present study point to the importance of
progressive osteophytosis in the course of early KOA. It is known
that osteophytes represent areas of new cartilage and bone for-
mation35. Osteophyte formation starts with chondrogenesis within
ﬁbrous mesenchymal tissue, which then results in a cartilage-like
structure called a chondrophyte. Thereafter, the core of the chon-
drophyte undergoes ossiﬁcation (chondro-osteophyte). Eventually,
the entire structure turns into bone (osteophyte)36. There are at
least two possible explanations for the associations between pro-
gressive osteophytosis and higher levels of bone markers. Firstly,
the higher levels of bone markers, especially bone formation
marker, presumably reﬂect the ossiﬁcation stage of osteophyte
formation. Secondly, as type I collagen is present also in soft tissues,
e.g., mensici, ligaments and tendons, higher values of sPINP might
also reﬂect changes in soft tissues that might accompany progres-
sive osteophytosis37,38.
The present study is the ﬁrst to investigate the value of the
novel bone resorption marker MidOC in early-stage KOA. We
found that among all other bone markers, MidOC was the stron-
gest risk predictor of progressive osteophytosis e a conclusion
that was reached by two different statistical methods e logistic as
well as by Poisson regression analysis (Table IV; Appendix). At the
same time we did not observe any risk association between the
other bone resorption marker, CTx-I, and progressive KOA. Thus,
we agree with conclusions from previous studies that used only
CTx-I and did not ﬁnd any difference in its value for OA pro-
gressors and non-progressors.
It seems reasonable to assume that OA is a disease affecting
mainly articular cartilage and may be better reﬂected by
changes in cartilage biomarkers. Our previous KOA study on
cartilage markers39 demonstrated that a cartilage degradation
marker, cartilage oligomeric matrix protein (COMP), serves as
another potent risk predictor for TF osteophytosis [OR ¼ 1.41, 95%
conﬁdence interval (CI) 1.056e1.870, P ¼ 0.020]37. However, a
comparison of the ORs of COMP and MidOC for predicting pro-
gressive osteophytosis (OR 1.41 vs 5.32 resp.) allowed us to
conclude that in early-stage KOA changes in bone metabolism are
not only present but can even dominate over changes in
cartilage.
Thus, our ﬁndings from patients with early ROA demonstrate
the activation of bone metabolism in the case of progressive
disease. Prior to ROA progression, we observed an activation of
reparative processes in bone (by PINP) that eventually turned out
to be inefﬁcient. Later, we documented ROA progression, which
was accompanied by an activation of all aspects of bone turnover
(by PINP, OC, MidOC). Resorption of the non-collagenous bone
(by MidOC) seems to be enhanced before the degradation of
collagen type I (by CTx-I). Three of the studied bone markers
(PINP, OC, MidOC) had diagnostic value for progressive osteo-
phytosis, and one of them, PINP, had prognostic value for pro-
gressive osteophytosis, as well as for more extensive cases of OA
progression (simultaneous OA progression in several knee
compartments).
J. Kumm et al. / Osteoarthritis and Cartilage 21 (2013) 815e822820Our study has some limitations. The studywas performed on the
basis of a relatively limited material. This might explain why some
potential associations might not have reached statistical signiﬁ-
cance. The bone markers PINP, CTx-I and OC were assayed at three
different time points and MidOC, only once. Therefore, possible
dynamic shifts in bone metabolism between the follow-up periods
may have been missed. As serum and urinary concentrations of
biomarkers reﬂect the systemic turnover of all synovial joints, any
speciﬁc alteration in the knee joints may have been masked by
changes in other joints e a drawback of any study based on sys-
temic biochemical assays. Articular soft tissue changes have an
effect on the systemic concentrations of biomarkers37. Further
studies using larger patient cohorts would possibly help to disclose
more information about metabolic changes in early KOA.
In conclusion, through studying middle-aged subjects with
early-stage ROA, we gained some new insights into OA-affected
bone turnover and proposed a possible sequence of metabolic
events. We demonstrated that some biomarkers have a potential to
be used as the reﬂectors of activated bone metabolism in early
progressive ROA either in diagnostic or prognostic manner, espe-
cially for progressive osteophytosis. The present study was the ﬁrst
to investigate the value of the novel bonemarker MidOC in KOAe a
marker that, among all studied biomarkers, turned out to be the
strongest risk predictor for progressive osteophytosis.
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Appendix
Appendix Figs. 1e4. ROC curves for bone marker values predicting
KOA progression.
Appendix Fig. 1. ROC curve for bone marker OC values predicting
progressive TF osteophytosis.OA progression was here expressed only by progressive TF
osteophytosis (without simultaneous progressive TF JSN or PF
involvement) over ﬁrst 3 years of follow-up.
Bone marker OC was assayed at 3-year follow-up.
Sensitivity for ﬁxed speciﬁcity 0.95 was 0.13 (95% CI 0.03e0.43).
Sensitivity for ﬁxed speciﬁcity 0.90 was 0.38 (95% CI 0.16e0.65).
Sensitivity for ﬁxed speciﬁcity 0.80 was 0.44 (95% CI 0.21e0.70).
Appendix Fig. 2. ROC curve for bone marker MidOC values
predicting progressive TF osteophytosis.
OA progression was here expressed only by progressive TF
osteophytosis (without simultaneous progressive TF JSN or PF
involvement) over ﬁrst 3 years of follow-up.
Bone
marker*
Type of OA progression
over ﬁrst 3 years of follow-up
RR (95% CI) P value n
OC Isolated TF osteophytesy 1.04 (1.02e1.06) 0.0002 16
OC TF osteophytes þ TF JSNz 1.02 (1.00e1.03) 0.017 13
MidOC TF osteophytes 1.32 (1.07e1.62) 0.009 34
MidOC Isolated TF osteophytesy 1.64 (1.19e2.26) 0.002 16
MidOC TF þ PF osteophytes 1.19 (1.03e1.37) 0.016 44
RR e relative risk
All analyses were adjusted for age, gender, and BMI.
By Poisson regression analysis with robust error variance.
* All presented bone markers were assayed at 3-year follow-up (in 2005).
y OA progression expressed only by TF osteophytes without simultaneous
progressive TF JSN or PF involvement.
z OA progression only in the TF compartment (TF osteophytes and/or TF JSN),
without simultaneous PF involvement.
J. Kumm et al. / Osteoarthritis and Cartilage 21 (2013) 815e822 821Bone marker MidOC was assayed at 3-year follow-up.
Sensitivity for ﬁxed speciﬁcity 0.95 was 0.19 (95% CI 0.05e0.49).
Sensitivity for ﬁxed speciﬁcity 0.90 was 0.31 (95% CI 0.12e0.60).
Sensitivity for ﬁxed speciﬁcity 0.80 was 0.38 (95% CI 0.17e0.64).
Appendix Fig. 3. ROC curve for bone marker MidOC values
predicting progressive TF and PF osteophytosis.
OA progressionwas here expressed by the progressive TF and PF
osteophytosis in combination over ﬁrst 3 years of follow-up.
Bone marker MidOC was assayed at 3-year follow-up.
Sensitivity for ﬁxed speciﬁcity 0.95 was 0.10 (95% CI 0.03e0.28).
Sensitivity for ﬁxed speciﬁcity 0.90 was 0.21 (95% CI 0.09e0.41).
Sensitivity for ﬁxed speciﬁcity 0.80 was 0.31 (95% CI 0.17e0.50).
Appendix Fig. 4. ROC curve for bone marker PINP values predicting
extensive KOA progression.Extensive progression e simultaneous progressive osteophy-
tosis with or without progressive JSN in multiple knee joint com-
partments over ﬁrst 3 years of follow-up.
Bone marker PINP was assayed at baseline.
Sensitivity for ﬁxed speciﬁcity 0.95 was 0.36 (95% CI 0.12e0.71).
Sensitivity for ﬁxed speciﬁcity 0.90 was 0.36 (95% CI 0.12e0.71).
Sensitivity for ﬁxed speciﬁcity 0.80 was 0.64 (95% CI 0.31e0.87).
Appendix Table 1. Statistically signiﬁcant associations between
bone markers and radiographic subgroups of KOA progression:
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